Finding a Floor Price, page-20

Correct. They would like to buy the IP as all the rest maybe is not so relevant.

The main question is:
"
If the technology is so outstanding and works, but is just kept on the sidelines from a regulatory body, based on what the market value the whole project almost zero?

Is really true that with a OK from the regulatory body, the company will be able to deliver the plan?

What is missing in this project, beside the low confidence factor from the shareholders, that has taken this company from being a market promise full of potential to be a a dead cat with zero interest?

Is normal, with such an outstanding product and a unique technology, to have doubled the number of shares outstanding in 5 years and taken down the share price from about 0.70 to 0.09 cents?

What is missing here that make the whole issue so unclear?
"

I am in the biotech market from many years, especially the Canadian and US market, but this is quite odd.
In general, such debacle is more related to companies that have failed the tests and clinical trials in Phase 2 (the technology does not work), but here the situation is different as it is stated everywhere that the technology works but it is just the regulatory hassle that drag the whole project down.
With such scenario, due that the technology works, it should be relatively easy to find a partner.
But instead nobody shows off and we looks terribly small.

True is that the fact that the IP is bound to a QUT contract that has some certain conditions, but they are not onerous (a share price of A$1 and A$100,000). This at today price is equal to A$ 30,100,000. ((300,000,000 shares at A$1)+A$100,000)
True the fact that such expense 5 years ago was equal to half of today price as the shares issued were 1/2 of today. Therefore, by absurd with the current structure the IP is more valuable today than 5 years ago for QUT and this is very unfair for the shareholders and require an immediate clarification by the management and if this si the case it must renegotiated immediately at lower terms if not (after A$ 60,000,000 invested by the shareholders in the company), transferred immediately to the Company.
We have paid for this, and is not fair that after having paid for many years R&D to QUT, they actually have now right for the IP pending A$ 30,100,000 to be paid to them.
This is very unfair.

We need a suitor, but is time that we remove the Poison Pills from the structure.
There is no need and the market want to see changes.
If there are no real changes to this, and we make the Company tasty for a major market player, we are going to keep the Damocles Sword on our heads.

Please, share your comments on the above. If I am wrong, please show me the contrary. It helps to understand.

Time is critical and major changes are needed together with more Transparency.

We need to look suitable for a bid, before even we look for a bidder.